Gerresheimer AG (0NTI) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Gerresheimer AG €19.17, price €27.75, upside -30.9%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €15.59 – €120.29 · fair‑value band €12.81 – €27.80 · the €27.75 price screens above the €19.17 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies.
Show more
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. It serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG has strategic collaboration with Newel Health to support pharma companies in integrated digital therapies. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.
Stock analysis
Gerresheimer AG (0NTI) currently trades at €27.75, while our model-based Fair Value estimate is €19.17, 30.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €17.96 per share, and 3 of the 23 models we run sit above the €27.75 price.
Bear case: the Dividend Discount group reads lowest at €4.70, and 20 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: €12.81 (bear) to €27.80 (bull), the price of €27.75 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Gerresheimer AG reported revenue of €1.4B in FY2020 versus €1.4B in FY2016, a compound +0.8%/yr. Reported net income was €88.6M in FY2020, compounding −7.6%/yr from FY2016.
Key figures
Market cap €2.5B · P/S ratio 1.07 · Net margin 6.2% · Return on equity −24.4% · Return on assets (EBIT) 6.2% · Operating margin 5.0% · Revenue (TTM) €2.3B · Revenue growth (YoY) +22.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 78% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −31%, 0NTI screens cheaper than that median.
Fair Value models
Bear €12.81Fair Value €19.17Bull €27.80
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+1.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
13.1% (2016) → 11.0% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gerresheimer AG Fair Value". https://www.fairvalue-calculator.com/stock/0NTI
Frequently asked questions
Is Gerresheimer AG (0NTI) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €19.17 versus a price of €27.75, about −31% upside (overvalued).
What is the fair value of 0NTI?
Our model-based fair value for Gerresheimer AG is €19.17 (as of Sep 24, 2026), built from audited fundamentals. The current price: €27.75.
What is the quality score of 0NTI?
Gerresheimer AG has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gerresheimer AG (0NTI)?
Our model-based price target is the fair value of €19.17 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario €12.81, optimistic scenario €27.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Gerresheimer AG stock forecast for 2026?
Our models put fair value at €19.17, about −31% upside versus a price of €27.75 (overvalued). Cautious scenario €12.81, optimistic scenario €27.80. The calculation is refreshed regularly with new filings.
What is the revenue of Gerresheimer AG (0NTI)?
Gerresheimer AG reported trailing-twelve-month revenue of about €2.3B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Gerresheimer AG (0NTI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gerresheimer AG it is €19.17 per share (as of Sep 24, 2026), against a price of €27.75. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Gerresheimer AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0NTI trades above its calculated fair value: price €27.75, fair value €19.17, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0NTI?
No. The price is what the market pays today (€27.75); the fair value is what the company's own numbers justify (€19.17). For Gerresheimer AG the two are €8.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gerresheimer AG worth?
The market values Gerresheimer AG at about €2.5B (market capitalisation, as of Sep 24, 2026). Per share that is €27.75; our models calculate a fair value of €19.17 per share.
What do the bullish and bearish scenarios say about 0NTI?
Our models span a range for Gerresheimer AG: cautious scenario €12.81, base €19.17, optimistic €27.80 per share (as of Sep 24, 2026, price €27.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0NTI from its 52-week high?
Gerresheimer AG trades at €27.75, about 27% below its 52-week high of €38.11 and 78% above the low of €15.59 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €19.17 is for.
Which stocks are comparable to Gerresheimer AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gerresheimer AG stock attractive at the current price?
The data as of Sep 24, 2026: price €27.75, calculated fair value €19.17 (−31%), Quality Score 55/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0NTI calculated?
We run Gerresheimer AG through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €19.17, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Gerresheimer AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gerresheimer AG (0NTI)?
The closing price on Oct 2, 2026 was €27.75. Our model-based fair value is €19.17, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gerresheimer AG right now?
Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€12.81 to €27.80) leaves room in how you read the outcome.
Key figures of Gerresheimer AG
How large is the market capitalisation of Gerresheimer AG (0NTI)?
The market capitalisation of Gerresheimer AG is €2.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gerresheimer AG (0NTI)?
The price-to-sales ratio of Gerresheimer AG is 1.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Gerresheimer AG (0NTI)?
The net margin of Gerresheimer AG is 6.2% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gerresheimer AG (0NTI)?
The return on equity (ROE) of Gerresheimer AG is −24.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gerresheimer AG (0NTI)?
On an EBIT basis the return on assets of Gerresheimer AG is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gerresheimer AG (0NTI)?
The operating margin of Gerresheimer AG is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gerresheimer AG (0NTI)?
Revenue at Gerresheimer AG is growing +22.0% versus a year earlier (3y avg +1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gerresheimer AG (0NTI)?
Earnings per share at Gerresheimer AG are growing −47.6% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
